Press Releases

WORLD INTELLECTUAL PROPERTY DAY | PROTECTING IP ASSETS, HANSOH PHARMA IS IN ACTION

EARTH DAY | PRACTICING GREEN DEVELOPMENT, HANSOH PHARMA ON THE WAY

EXPAND FIRST-LINE TREATMENT WITH COMBINED CHEMOTHERAPY – ANOTHER REGISTERED CLINICAL STUDY OF ALMONERTINIB WAS APPROVED

GOLD SHINES BRIGHTER AFTER COMING OUT FROM FIRE丨HANSOH XINFU'S REAL-WORLD CLINICAL EFFECT IS HIGHLY RECOGNIZED

CLINICAL RECRUITMENT | SUBJECT RECRUITMENT FOR USE OF ALMONERTINIB IN TREATMENT OF NON-PROGRESSIVE NSCLC AFTER RADICAL PLATINUM-CONTAINING CHEMORADIOTHERAPY

CLINICAL RECRUITMENT | SUBJECT RECRUITMENT FOR USE OF ALMONERTINIB IN POSTOPERATIVE ADJUVANT THERAPY OF NSCLC

SCYNEXIS AND HANSOH PHARMA ANNOUNCE LICENSING AGREEMENT AND STRATEGIC PARTNERSHIP FOR IBREXAFUNGERP IN GREATER CHINA

FOUR DRUGS OF HANSOH PHARMA WON THE BID IN CHINA'S FOURTH-ROUND NATIONAL CENTRALIZED DRUG PROCUREMENT, EXTENDING BENEFITS TO MORE PATIENTS